Business Context and Reporting Period
Company: Synaptogenix, Inc. (SNPX)
Filing Type: Form 8-K (Current Report)
Date of Report: September 10, 2024
Event: Entry into a Material Definitive Agreement for a capital raise consisting of a Registered Direct Offering and a concurrent Private Placement.
Key Financial Metrics and Transaction Details
Aggregate Gross Proceeds: Expected to be $5.0 million.
Use of Proceeds: General corporate purposes, including research and development, clinical trial expenses, capital expenditures, and working capital.
Securities Issued:
- Registered Offering: 1,793 shares of Series C Convertible Preferred Stock (stated value $1,000/share), convertible into up to 448,250 shares of Common Stock.
- Private Placement: 3,207 shares of Series C Convertible Preferred Stock, convertible into up to 801,750 shares of Common Stock, plus warrants to acquire up to 1,250,000 shares of Common Stock.
Conversion Terms: Initial conversion price of $4.00 per share. Subject to full ratchet anti-dilution adjustments.
Dividends: 5% per annum compounded quarterly (payable in cash); increases to 15% per annum upon a "Triggering Event."
Redemption Obligations: Mandatory quarterly redemption installments commencing October 31, 2024, payable at 107% of the installment amount.
Placement Agent Fees: 7.0% cash fee of gross proceeds plus warrants equal to 3.0% of the initial conversion shares (exercise price $4.00, 5-year term).
Material Changes and Agreements
The filing details the execution of a Securities Purchase Agreement and a Registration Rights Agreement. Key material terms include:
- Registration Rights: The Company must file a resale registration statement covering 200% of the unregistered conversion shares and warrant shares within 30 days of the agreement's effective date.
- Stockholder Approval: The Company must seek stockholder approval for the issuance of shares exceeding 19.99% of outstanding common stock by December 31, 2024, to comply with Nasdaq listing standards.
- Covenants: The agreement includes affirmative and negative covenants regarding indebtedness, acquisitions, liens, and asset transfers.
- Triggering Events: Defined events (e.g., failure to file registration statements or pay amounts due) allow holders to demand immediate redemption at a premium and increase dividend rates to 15%.
Outlook, Risks, and Contingencies
Closing Date: Expected on September 12, 2024, subject to customary conditions.
Liquidity and Redemption Risk: The mandatory quarterly redemption schedule starting October 31, 2024, creates a near-term cash outflow obligation. The Company's ability to settle conversions is limited until stockholder approval is obtained.
Dilution Risk: The transaction involves significant potential dilution through the conversion of preferred shares and the exercise of warrants, with full ratchet protection for investors.
Market Status: There is no established public trading market for the Series C Preferred Shares or the Warrants.
Investor Verification Checklist
- Verify the Company's current cash position and ability to meet the mandatory quarterly redemption payments starting October 31, 2024.
- Confirm the timeline and likelihood of obtaining stockholder approval by December 31, 2024, to enable full conversion of shares.
- Review the specific definition of "Triggering Events" in the Certificate of Designations to assess the risk of accelerated redemption and increased dividend costs.
- Assess the impact of the 7% cash fee and warrant issuance on the net proceeds available for operations.
- Monitor the filing of the resale registration statement required within 30 days to avoid liquidated damages.